Published by EBStatMax team
Clinical Trial DesignResearch and Drug DevelopmentLearning Video on the EBStatMax statistical recommendations
View this resource Bookmark this resourcePublished by EBStatMax team
Clinical Trial DesignResearch and Drug DevelopmentPublished by EBStatMax team
Clinical Trial DesignResearch and Drug DevelopmentPublished by Wiley
Clinical Trial DesignResearch and Drug DevelopmentPeer reviewed journal article on a neutral comparison of statistical methods for longitudinal ordinal outcomes
View this resource Bookmark this resourcePublished by Oxford Academic
Clinical Trial DesignResearch and Drug DevelopmentPeer reviewed journal article on a neutral comparison of statistical methods for longitudinal count data and binary data
View this resource Bookmark this resourcePublished by Springer
Clinical Trial DesignResearch and Drug DevelopmentPeer reviewed journal article on statistical recommendations for longitudinal cross-over studies in rare disease research
View this resource Bookmark this resourcePublished by EBStatMax team
Clinical Trial DesignResearch and Drug DevelopmentPublished by IRDiRC
Act on Medical CareEarly Access SupportMHLW or PMDA RegulatoryNan-byo DesignationRare DiseaseRegulatory AffairsDefinition of designated Nan-byo is provided in the law named “Act on Medical Care for Patients with Intractable/Rare Diseases”. Patients with designated Nan-byo can receive financial support for medical treatment
View this resource Bookmark this resourcePublished by
clinicalmedicineNon-ClinicalQualityRegulatory AdviceScientific AdviceEMA Medicine finder helps find information on medicines authorised for human or veterinary use. You can find these by including the medicine’s name or its active substance. It shows information on centrally authorised medicines – medicines that EMA evaluated.
View this resource Bookmark this resourceThe European Medicines Agency’s (EMA) Emergency Task Force (ETF) provides scientific advice to developers of medicines used in declared or potential public health emergencies and threats.
View this resource Bookmark this resource